A double-blind, randomized, multicenter, placebo-controlled, parallel-group efficacy study of MK0928 15 mg and 10 mg in the treatment of adult outpatients with primary insomnia

Trial Profile

A double-blind, randomized, multicenter, placebo-controlled, parallel-group efficacy study of MK0928 15 mg and 10 mg in the treatment of adult outpatients with primary insomnia

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2015

At a glance

  • Drugs Gaboxadol (Primary)
  • Indications Insomnia
  • Focus Registrational; Therapeutic Use
  • Sponsors Lundbeck A/S; Merck & Co
  • Most Recent Events

    • 03 Aug 2008 Additional trial identifier MK0928-014 reported by ClinicalTrials.gov.
    • 19 May 2007 Status changed from in progress to completed.
    • 07 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top